Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma

TY - JOUR

T1 - Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma

AU - PiCA and SysPharmPedia consortia

AU - Hernandez-Pacheco, Natalia

AU - Gorenjak, Mario

AU - Jurgec, Staša

AU - Corrales, Almudena

AU - Jorgensen, Andrea

AU - Karimi, Leila

AU - Vijverberg, Susanne J.

AU - Berce, Vojko

AU - Schieck, Maximilian

AU - Acosta-Herrera, Marialbert

AU - Kerick, Martin

AU - Samedy-Bates, Lesly-Anne

AU - Tavendale, Roger

AU - Villar, Jesús

AU - Mukhopadhyay, Somnath

AU - Pirmohamed, Munir

AU - Verhamme, Katia M. C.

AU - Kabesch, Michael

AU - Hawcutt, Daniel B.

AU - Turner, Steve

AU - Palmer, Colin N.

AU - Burchard, Esteban G.

AU - Maitland-van der Zee, Anke H.

AU - Flores, Carlos

AU - Potočnik, Uroš

AU - Pino-Yanes, Maria

N1 - Funding Information: NH‐P declares funding from Instituto de Salud Carlos III (ISCIII) and the European Social Funds. SM reports funding from The Gannochy Trust, Perth and Kinross City Council, and Scottish Enterprises Tayside. MP declares funding from the MRC Clinical Pharmacology Training Scheme, EPSRC, Astra Zeneca, and Bristol Myers Squibb. KV reports funding from ZonMw, Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, and GSK. MK declares funding from the European Union, German Ministry of Education, Research, German Research Foundation, and other sources. EGB reports funding from the National Institute of Health, National Institute of Health and Environmental Health Sciences, National Institute on Minority Health and Health Disparities, National Institute of General Medical Sciences, National Human Genome Research Institute, Sandler Family Foundation, American Asthma Foundation, and Robert Wood Johnson Foundation. A‐HM declares funding from GlaxoSmithKline, Boehringer Ingelheim, and Astra Zeneca. UP reports funding from the Slovenian Research Agency and the Ministry of Education, Science, and Sport of Slovenia. MP‐Y declares funding from ISCIII, the Spanish Ministry of Science, Innovation, and Universities, and Spanish Ministry of Economy, Industry, and Competitiveness. Funding Information: This study was supported by the award (AC15/00015) funded by the Instituto de Salud Carlos III (ISCIII) through Strategic Action for Health Research (AES) and European Community (EC) within the Active and Assisted Living (AAL) Programme framework (MP‐Y), and the SysPharmPedia grant from the ERACoSysMed 1 Joint Transnational Call from the European Union under the Horizon 2020. This study was also funded by the Spanish Ministry of Science, Innovation, and Universities, the State Research Agency, and the European Regional Development Funds from the European Union (MICIU/AEI/FEDER, UE, SAF2017‐83417R). N.H‐P was supported by a fellowship (FI16/00136) from Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Social Funds from the European Union (ESF) “ESF invests in your future.” MP‐Y was funded by the Ramón y Cajal Program (RYC‐2015‐17205) by the Spanish Ministry of Economy, Industry, and Competitiveness. The PACMAN study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). GALA II was supported by the National Heart, Lung, and Blood Institute of the National Institute of Health (NIH) grants R01HL117004 and X01HL134589; study enrollment supported by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II and the National Institute of Environmental Health Sciences grant R01ES015794. SAGE was funded by the National Heart, Lung, and Blood Institute of the National Institute of Health (NIH) grants R01HL117004 and X01HL134589; study enrollment supported by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II. The SHARE Bioresource (GoSHARE) and SHARE have ongoing funding from NHS Research Scotland and established by funding from the Wellcome Trust Biomedical Resource [Grant No. 099177/Z/12/Z]. ESTATe was funded by an independent research grant by ZonMw project (113201006). The PASS study was funded by the NHS Chair of Pharmacogenetics via the UK Department of Health. MP is Emeritus NIHR Senior Investigator. Genotyping of samples from BREATHE‐PAGES, GoSHARE, and SCSGES was carried out at CeGen‐PRB3‐ISCIII, and supported by ISCIII and European Regional Development Fund (ERDF) (PT17/0019). st

PY - 2021/4/11

Y1 - 2021/4/11

KW - asthma treatment

KW - childhood asthma

KW - exacerbations

KW - genetic polymorphism

KW - pharmacogenomics

UR - https://www.scopus.com/pages/publications/85090972491

U2 - 10.1111/all.14552

DO - 10.1111/all.14552

M3 - Letter

C2 - 32786158

SN - 0105-4538

VL - 76

SP - 1238

EP - 1243

JO - Allergy

JF - Allergy

IS - 4

ER -